EX-13

Exhibit 13

Meridian Bioscience, Inc. and Subsidiaries

SELECTED FINANCIAL DATA

Income Statement Information (Amounts in thousands except for per share data)


	FY 2008		FY 2007		FY 2006		FY 2005		FY 2004

Net sales	$	139,639	$	122,963	$	108,413	$	92,965	$	79,606
Gross profit		86,480		74,940		64,684		54,890		45,955
Operating Income		44,350		35,030		26,894		20,325		14,956
Net earnings		30,202		26,721		18,333		12,638		9,366
Basic earnings per share	$	0.75	$	0.67	$	0.47	$	0.36	$	0.28
Diluted earnings per share	$	0.74	$	0.66	$	0.46	$	0.35	$	0.27
Cash dividends declared per share	$	0.53	$	0.40	$	0.28	$	0.21	$	0.17
Book value per share	$	3.19	$	2.83	$	2.40	$	2.14	$	0.96

Balance Sheet Information


	FY 2008		FY 2007		FY 2006		FY 2005		FY 2004

Current assets	$	99,458	$	93,745	$	80,742	$	69,725	$	35,603
Current liabilities		16,061		17,067		20,617		19,791		16,650
Total assets		146,431		132,698		120,528		110,134		68,814
Long-term debt obligations		—		—		1,803		2,684		17,093
Shareholders’ equity		128,489		112,948		94,350		83,333		32,424

FORWARD LOOKING STATEMENTS

The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this Annual Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which may be identified by words such as “estimates”, “anticipates”, “projects, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. The Company assumes no obligation to publicly update any forward-looking statements whether as a result of new information or to reflect events or circumstances arising after the date on which they are made. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including without limitation, the following:

Meridian’s continued growth depends, in part, on its ability to introduce into the marketplace enchancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Costs and difficulties in complying with laws and regulations administered by the United States Food and Drug Administration can result in unanticipated expenses and delays and interruptions to the sale of new and existing products. Changes in the relative strength or weakness of the U.S. dollar can change expected results. One of Meridian’s main growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses successfully integrated into Meridian’s operations. In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our Form 10-K contains a list of uncertainties and risks that may affect the financial performance of the Company.

CORPORATE PROFILE

Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral, and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company’s shares are traded through NASDAQ’s Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.

MERIDIAN BIOSCIENCE, INC.

		(1) If such Event of Default is a Senior Payment Default, the payment in full in cash of all amounts due with respect to such Senior Payment Default; or

		(1) If such Event of Default is a Senior Payment Default, the payment in full in cash of all amounts due with respect to such Senior Payment Default; or


Corporate Data		Meridian Bioscience, Inc. and Subsidiaries

Corporate Headquarters 3471 River Hills Drive Cincinnati, Ohio 45244 (513) 271-3700		Annual Meeting The annual meeting of the shareholders will be held on Tuesday, January 22, 2009 at 2:00 p.m. Eastern Time at the Holiday Inn Eastgate, 4501 Eastgate Boulevard, Cincinnati,

		OH 4S245.
Legal Counsel Keating Muething & Klekamp PLL Cincinnati, Ohio		Directions to the Holiday Inn Eastgate can be found on our website: www.meridianbioscience.com.

Independent Public Accountants Grant Thornton LLP Cincinnati, Ohio

Transfer Agent, Registrar and Dividend Reinvestment Administration
Shareholders requiring a change of name, address or ownership of stock, as well as information about shareholder records, lost or stolen certificates, dividend checks, dividend direct deposit, and dividend reinvestment should contact: Computershare Investor Services LLC, P. O. Box 43078, Providence, RI 02940-3078; (888) 294-8217 or (312) 601-4332:
e-mail web.queries@computershare.com; or submit your inquiries online through www.computershare.com/contactus.

Common Stock Information

NASDAQ Global Select Market Symbol: “VIVO.” Approximate number of beneficial holders: 26,000. Approximate number of record holders: 900.

The following table sets forth by calendar quarter the high and low sales prices of the Common Stock on the NASDAQ Global Select Market.


Years Ended September 30,	2008				2007
Quarter ended:	High		Low		High		Low

December 31		34.240		26.500		17.160		13.840
March 31		36.090		28.910		19.950		16.250
June 30		37.000		25.200		22.470		18.390
September 30		30.500		23.250		31.200		21.300

Directors and Officers


Directors		Officers

William J. Motto Executive Chairman of the Board John A. Kraeutler Chief Executive Officer James A. Buzard, Ph.D. Retired Executive Vice President, Merrell Dow Pharmaceuticals, Inc. Gary P. Kreider Senior Partner, Keating Muething & Klekamp PLL Robert J. Ready Chairman of the Board and President, LSI Industries Inc. David C. Phillips Co-founder, Cincinnati Works, Inc.		William J. Motto Executive Chairman of the Board John A. Kraeutler Chief Executive Officer Richard L. Eberly Executive Vice President, President Meridian Life Science Lawrence J. Baldini Executive Vice President, Operations and Information Systems Grady Barnes Vice President, Research and Development Antonio A. Interno Senior Vice President, President and Managing Director, Meridian Bioscience Europe Melissa A. Lueke Vice President, Chief Financial Officer Susan D. Rolih Senior Vice President, Regulatory Affairs and Quality Assurance Todd W. Motto Vice President, Sales and Marketing

PERFORMANCE GRAPH

The following graph shows the yearly percentage change in Meridian’s cumulative total shareholder return on its Common Stock as measured by dividing the sum of (A) the cumulative amount of dividends, assuming dividend reinvestment during the periods presented and (B) the difference between Meridian’s share price at the end and the beginning of the periods presented; by the share price at the beginning of the periods presented with the Wilshire 5000 Equity Index and a Peer Group Index. The Peer Group consists of Biomerica, Inc., Idexx Laboratories Corp., Inverness Medical Innovations, Invitrogen Corp., Neogen Corp., Orasure Technologies Inc., Quidel Corp., Strategic Diagnostics Inc. and Trinity Biotech Plc.

COMPARISON OF 5 YEAR CUMULATIVE TOTAL RETURN*

Among Meridian Bioscience, Inc., The Dow Jones Wilshire 5000 Index
And A Peer Group


*		$100 invested on 9/30/03 in stock & index-including reinvestment of dividends.

Fiscal year ending September 30.